The U.S. Food and Drug Administration has issued draft guidance on the agency's current policy of accepting scientifically valid clinical data obtained from foreign clinical studies in support of premarket submissions for medical devices.
The draft guidance describes special considerations that apply when using such data, including applicability to populations within the U.S., to ensure data are adequate under applicable FDA standards.
Register or login for access to this item and much more
All Health Data Management content is archived after seven days.
Community members receive:
- All recent and archived articles
- Conference offers and updates
- A full menu of enewsletter options
- Web seminars, white papers, ebooks
Already have an account? Log In
Don't have an account? Register for Free Unlimited Access